Origin of Hypofunctional CD103+ NK Cells in Cirrhosis-Associated Ascites
- PMID: 40498379
- PMCID: PMC12154167
- DOI: 10.1002/eji.202451311
Origin of Hypofunctional CD103+ NK Cells in Cirrhosis-Associated Ascites
Abstract
The occurrence of ascites is a frequent complication associated with the decompensation of liver cirrhosis. While it is known that cirrhosis leads to altered immune responses in the periphery, the immunological milieu of ascites remains poorly understood. In this study, we investigate the role and origin of natural killer (NK) cells in cirrhosis-associated ascites. Using high-dimensional flow cytometry and cytokine analysis, we analyzed matched peripheral blood and ascites fluid alongside liver and duodenum samples to discern tissue-specific differences. Interestingly, a subset of peritoneal NK cells displayed high expression of the tissue-residency receptor CD103. This subset of CD103+ ascites NK cells was distinct from blood, liver, and intestinal NK cells and presented with a less activated phenotype coupled with reduced effector capacity. Investigating their origin, we could identify that cytokines present in ascites, here predominantly IL-15 in synergy with IL-21 and TGFβ, can induce CD103 expression and that ascites supernatant further facilitates this process. These results indicate that the ascites in patients with decompensated liver cirrhosis harbor a heterogenous subset of CD103+ NK cells that is likely induced by the cytokine milieu.
Keywords: gut leakage; liver cirrhosis; natural killer cells; peritoneal cavity.
© 2025 The Author(s). European Journal of Immunology published by Wiley‐VCH GmbH.
Conflict of interest statement
BM served as a speaker and/or advisory board member for AbbVie, AstraZeneca, EWIMED, Fujirebio, Gilead, Luvos, MSD, Norgine, Roche, and W. L. Gore & Associates and received research support from Altona, EWIMED, Fujirebio, and Roche. MC reports receiving lecture and/or consulting fees from AbbVie, AiCuris, AstraZeneca, Falk, Gilead, GSK, MSD Sharp & Dohme, and Roche, outside the scope and topic of this study. HW served as a speaker / advisory board member for Abbott Laboratories & Abbott Molecular, Albireo Pharma, AstraZeneca, Atea Pharmaceuticals, Bristol‐Myers‐Squibb, Dr. Falk Pharma, Hoffmann‐La Roche, Gilead Sciences GmbH & Gilead Sciences Ltd., GlaxoSmithKline Services Unlimited, Janssen, Lilly Deutschland, Mirum Pharmaceuticals, MSD Sharp & Dohme, Orphalan, Pfizer, Roche Diagnostics International, Sobi, Takeda, Vir Biotechnology, received research support from Abbott Laboratories & Abbott Molecular, Biotest AG and received lecture fees from Biotest AG, BioMarin Pharmaceuticals, CSL Behring, Falk Foundation and Olink. The remaining authors declare no conflicts of interest.
Figures






References
-
- Albillos A., Lario M., and Alvarez‐Mon M., “Cirrhosis‐associated Immune Dysfunction: Distinctive Features and Clinical Relevance,” Journal of Hepatology 61 (2014): 1385–1396. - PubMed
-
- Bonnel A. R., Bunchorntavakul C., and Reddy K. R., “Immune Dysfunction and Infections in Patients With Cirrhosis,” Clinical Gastroenterology and Hepatology 9 (2011): 727–738. - PubMed
-
- Nadim M. K., Durand F., Kellum J. A., et al., “Management of the Critically Ill Patient with Cirrhosis: A Multidisciplinary Perspective,” Journal of Hepatology 64 (2016): 717–735. - PubMed
-
- Teli M. R., Day C. P., Burt A. D., et al., “Determinants of Progression to Cirrhosis or Fibrosis in Pure Alcoholic Fatty Liver,” Lancet 346 (1995): 987–990. - PubMed
-
- D'Amico G., Garcia‐Tsao G., and Pagliaro L., “Natural History and Prognostic Indicators of Survival in Cirrhosis: A Systematic Review of 118 Studies,” Journal of Hepatology 44 (2006): 217–231. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials